Kedudukan dalam Saham
#41656
Established in 1997 and headquartered in Pencoed, UK, ReNeuron Group plc... Established in 1997 and headquartered in Pencoed, UK, ReNeuron Group plc focuses on the research, development, and commercialization of innovative cell-based therapies. The company is actively developing a CTX stem cell therapy candidate targeting stroke disability, which is currently at the partnering stage for distribution both within and outside China. Another significant pipeline asset is its human retinal progenitor cell therapy, now in Phase I/IIa clinical trials, designed to treat retinitis pigmentosa, a debilitating eye disease leading to blindness. Furthermore, ReNeuron is conducting pre-clinical investigations into CTX-derived exosomes, which are microscopic, information-carrying packages released by CTX cells. The firm also generates revenue through the licensing of its ReNcell products. Collaboratively, ReNeuron has partnered with University College London to explore the creation of immune cells from induced pluripotent stem cells for application in anti-cancer cell therapies.
Harga Saham
$0.00042815
Disegerakkan terakhir: 2024-02-27
Perubahan (1 tahun)
0.00%
Perdagangan ReNeuron Group plc (RENE)
Harga RENE dengan permodalan pasaran b
Modal pasaran bagi ReNeuron Group plc(RENE)
Modal Pasaran: $13.55K
Sehingga August 2026, ReNeuron Group plc mempunyai modal pasaran sebanyak $13.55K. Ini menjadikan ReNeuron Group plc syarikat ke-41656th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran ReNeuron Group plc dari 2005 hingga 2026
RENE berbanding dengan 5 teratas yang paling popular stocks
| Harga RENE |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.383T
|
+39,731,415,695.48%
|
|
|
|
|
$4.423T
|
+32,646,453,559.22%
|
|
|
|
|
$4.160T
|
+30,705,244,029.79%
|
|
|
|
|
$3.663T
|
+27,036,820,392.59%
|
|
|
|
|
$2.891T
|
+21,338,462,301.30%
|
